How many insider declarations has ARCH Venture Partners X, LLC filed?

ARCH Venture Partners X, LLC has filed 10 public insider declarations with SEC (Form 4).

What is ARCH Venture Partners X, LLC's role?

ARCH Venture Partners X, LLC's reported role is not specified by the regulator across the filings.

Which companies does ARCH Venture Partners X, LLC report trades for?

ARCH Venture Partners X, LLC reports trades for 4 companies, including Verve Therapeutics, Inc..

What is ARCH Venture Partners X, LLC's declared buy vs sell volume?

Across the available history, declared buys total 18.6M€ and disposals 0.

← Executives ★ Sign in to follow

AV

ARCH Venture Partners X, LLC

Other

US·SEC (Form 4)

Verve Therapeutics, Inc.Erasca, Inc.Prime Medicine, Inc.Neumora Therapeutics, Inc.

0

Total declarations

0

Companies

€19m

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Insider track record

Other

Disclosed buys

1

Disclosed sells

0

T+90 hit rate

0%

T+90 mean return

-1.2%

Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Browse the detailed record of transactions filed by ARCH Venture Partners X, LLC. Insider active across 4 companies, notably Verve Therapeutics, Inc.. Aggregated, 10 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €18.6m. Activity tracked since 15 February 2024. The latest transaction was filed on 15 February 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.

Declarations10 total

▲

ARCH Venture Partners X, LLC

Executives15 Feb 2024Prime Medicine, Inc.

$20M40SEC ↗

3,200,000 shares@ US$6.25100.0% of flowCommon StockSEC:0001062993-24-003738:0